生物谷(833266) - 2024 Q1 - 季度财报

Financial Performance - Net profit attributable to shareholders for Q1 2024 was CNY 10,529,264.31, representing a significant increase of 510.18% year-over-year[12] - Operating revenue for the first quarter of 2024 was CNY 154,441,052.85, reflecting a growth of 13.71% compared to the same period last year[12] - The company reported a basic earnings per share of CNY 0.08, up 700.00% from CNY 0.01 in the previous year[12] - The company’s total profit for Q1 2024 was CNY 13,247,437.80, an increase of 363.11% year-over-year[14] - The company reported a total comprehensive income for Q1 2024 of CNY 10,529,264.31, significantly higher than CNY 1,725,600.86 in Q1 2023, indicating a growth of approximately 510.5%[55] - The company's total profit for Q1 2024 was CNY 11,936,052.62, compared to CNY 1,249,419.76 in Q1 2023, representing an increase of about 855.5%[58] Cash Flow and Liquidity - The company's cash flow from operating activities increased by 21.17% to CNY 54,184,916.38 in Q1 2024[12] - The total cash and cash equivalents at the end of Q1 2024 reached CNY 205,555,244.94, up from CNY 155,106,733.08 on December 31, 2023, reflecting a growth of approximately 32.5%[47] - The net cash flow from operating activities for Q1 2024 was CNY 53,899,687.30, a significant increase from CNY 16,870,605.76 in Q1 2023, reflecting improved operational efficiency[64] - The company reported a net increase in cash and cash equivalents of CNY 53,522,401.85 for Q1 2024, compared to an increase of CNY 2,318,861.37 in Q1 2023, indicating strong cash generation[64] Assets and Liabilities - Total assets as of March 31, 2024, reached CNY 1,245,010,150.21, an increase of 0.75% compared to the end of 2023[12] - The total liabilities to assets ratio for the consolidated entity was 18.87%, a slight decrease from 19.12% at the end of 2023[12] - The company's total liabilities decreased to CNY 235,002,635.69 as of March 31, 2024, from CNY 236,223,971.63 on December 31, 2023, showing a reduction of approximately 0.5%[49] - The company's total equity increased to CNY 1,010,007,514.52 as of March 31, 2024, compared to CNY 999,478,250.21 on December 31, 2023, marking an increase of about 1.6%[49] Shareholder Changes and Legal Issues - The original controlling shareholder, Shenzhen Jinsanjian Investment Co., Ltd., held 30,000,000 shares (24.19% of total shares) before the judicial auctions[22] - After the auctions, the new controlling shareholder is Shanghai Xinhong, which acquired 32,851,219 shares (26.49% of total shares) from the original shareholders[23] - The company has initiated a civil lawsuit against Jinsanjian for a fund occupation balance of 257 million yuan[29] - The company received a notice from the Shenzhen Intermediate People's Court regarding a lawsuit involving Lin Yanhe and others, with the case accepted on August 17, 2022[30] - The original controlling shareholder, 金沙江, occupied funds totaling ¥257 million, with repayments of ¥39.06 million and ¥39.70 million made in 2021 and early 2022 respectively[34] Research and Development - Research and development expenses decreased by 41.95% to CNY 2,782,072.88 compared to the same period last year[14] - Research and development expenses decreased to CNY 2,697,325.40 in Q1 2024 from CNY 4,792,473.34 in Q1 2023, a reduction of approximately 43.7%[58] Inventory and Receivables - The company’s inventory decreased to CNY 98,256,192.51 as of March 31, 2024, down from CNY 108,244,983.82 on December 31, 2023, representing a decline of approximately 9.1%[47] - The company’s accounts receivable decreased to CNY 118,579,931.49 as of March 31, 2024, compared to CNY 131,839,929.98 on December 31, 2023, indicating a decrease of about 10%[47]